Treatments for pediatric hematologic malignancies precipitate cardiovascular injury via direct cardiotoxicity, inflammatory activation, and immune-mediated damage, offering new cardioprotective targets.
What are the mechanisms underlying cardiovascular events associated with the treatment of pediatric hematologic malignancies?
This review synthesizes the mechanisms of cardiovascular injury from cancer therapies in pediatric hematologic malignancies and identifies emerging cardioprotective targets.
This narrative review synthesizes the most recent advances in elucidating the mechanisms underlying cardiovascular events associated with the treatment of pediatric hematologic malignancies. First, this review delineates the principal therapeutic modalities currently employed, including chemotherapy, radiotherapy, cellular immunotherapy, and small-molecule targeted therapy. Subsequently, this review offers a systematic and nuanced appraisal of the mechanisms through which these treatments precipitate cardiovascular injury, encompassing direct cardiotoxic effects, inflammatory activation, and immune-mediated tissue damage. Finally, this review examines emerging therapeutic targets with potential relevance for intervention, to refine treatment strategies, mitigate cardiovascular adverse effects, and enhance both quality of life and long-term outcomes in affected children. This review integrates these mechanisms within a cohesive, pediatric-specific conceptual framework and highlights actionable cardioprotective targets across therapeutic modalities.
He et al. (Wed,) conducted a review in Pediatric hematologic malignancies. Cancer therapies (chemotherapy, radiotherapy, cellular immunotherapy, targeted therapy) was evaluated. Treatments for pediatric hematologic malignancies precipitate cardiovascular injury via direct cardiotoxicity, inflammatory activation, and immune-mediated damage, offering new cardioprotective targets.